Alexander Schubert is a PhD neuroscientist-turned-investor with deep expertise in alternative causes of neurodegeneration and prior R&D experience at Genentech, giving him unusually strong domain knowledge compared to most generalist VCs. He operates as both investor at SciFounders and Chief of Staff at fertility biotech Conception, while maintaining an active academic profile that positions him as a peer to technical founders rather than a purely financial investor.

• Enthusiasm for utilizing untapped biological resources, specifically animal venoms, as a source for the next generation of blockbuster drugs. Advocates for applying modern technologies like next-generation sequencing and physics-based molecular docking to this field, citing successful precedents such as GLP-1 agonists originally discovered in Gila monsters.
• Critical perspective on the current state of AI in protein design, noting that models often memorize training data rather than understanding physical laws. Emphasizes that large language models should serve only as a preliminary filter, requiring physics-based validation or experimental data to confirm that molecules will actually bind as predicted.
• Admiration for high-velocity execution in the biotech sector, particularly founders who can build and exit rapidly despite a tough fundraising climate. Highlights the trajectory of Metsera, which went from founding to a multi-billion dollar acquisition by Pfizer in roughly three years, as an impressive example of an obesity market speed run.
• Interest in advanced generative models that look at patient health holistically rather than isolating single diseases. Praises systems that use biobank data to simulate lifetime health trajectories and comorbidity risks, viewing these dynamic predictions as far more actionable than static risk scores.
• Attention to regulatory shifts that lower barriers for niche therapies. Tracks FDA updates regarding accelerated approval pathways for ultra-rare diseases, specifically those allowing for single-arm studies and flexible evidence like surrogate biomarkers to support companies treating very small patient populations.
• Specific desire to see automation applied to surgery rather than general-purpose robotics. Expressed a direct call for founders building autonomous surgical robots, dismissing humanoid robots as less compelling for his investment thesis.